A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the therapy.

Atai Life Sciences NV shares climbed after a psychedelic nasal spray from Beckley Psytech Ltd, the company it plans to ...

None have been approved by the Food and Drug Administration so far, though in 2019, Johnson & Johnson received FDA permission ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that the asset could hit peak market sales of $1 billion. The results clear the ...

Spravato nasal spray has been FDA approved to treat depression. Here's how the esketamine spray works, esketamine vs. ketamine, and potential risks.

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

Jan. 27, 2025 – After years of limited options, people with hard-to-treat depression finally have a new standalone treatment. The FDA’s latest approval of the nasal spray Spravato (esketamine ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is ...

The nasal spray has undergone more than a decade of research and nearly six years of real-world application. To date, Spravato has been administered to more than 140,000 patients worldwide.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.